iRECIST: A clarification of tumour response assessment in the immunotherapy era

Affiliations

¹ Early Drug Development Unit (DITEP), Gustave Roussy, Paris Saclay University, Villejuif, France; Head and neck cancer department, Gustave Roussy, Paris Saclay University, Villejuif, France; INSERM U1030, Gustave Roussy, Paris Saclay University, Villejuif, France. Electronic address: Charles.ferte@gustaveroussy.fr.
² Early Drug Development Unit (DITEP), Gustave Roussy, Paris Saclay University, Villejuif, France; INSERM U1015, Gustave Roussy, Paris Saclay University, Villejuif, France.

Editorial

Charles Ferté et al. Eur J Cancer. 2017 May.

. 2017 May:77:165-167.

doi: 10.1016/j.ejca.2017.02.015. Epub 2017 Apr 4.

¹ Early Drug Development Unit (DITEP), Gustave Roussy, Paris Saclay University, Villejuif, France; Head and neck cancer department, Gustave Roussy, Paris Saclay University, Villejuif, France; INSERM U1030, Gustave Roussy, Paris Saclay University, Villejuif, France. Electronic address: Charles.ferte@gustaveroussy.fr.
² Early Drug Development Unit (DITEP), Gustave Roussy, Paris Saclay University, Villejuif, France; INSERM U1015, Gustave Roussy, Paris Saclay University, Villejuif, France.

No abstract available

Comment in

Promising cancer drugs may speed tumours in some patients.
Ledford H. Ledford H. Nature. 2017 Mar 31;544(7648):13-14. doi: 10.1038/nature.2017.21755. Nature. 2017. PMID: 28383004 No abstract available.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. Seymour L, et al. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28271869 Free PMC article. Review.